Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Oragenics Inc chart...

About the Company

oragenics is a publicly-traded biopharmaceutical company with a pipeline of unique proprietary technologies. offerings are based on the probiora3 technology and brands include evoraplus™ is a new, one-of-a-kind probiotic mint that naturally supports gum and tooth health while freshening breath and whitening teeth. oragenics has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, in diagnostics, and in oral health.

Exchange

NYSE MKT LLC

Website

https://www.oragenics.com/

$5M

Total Revenue

18

Employees

$4M

Market Capitalization

-0.75

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $OGEN News

Oragenics Prices Public Offering Of 1.40 Mln Shares At $1.50/shr; Stock Plunges

1mon ago, source: Nasdaq

(RTTNews) - Oragenics Inc. (OGEN) announced the pricing of an underwritten public offering of 1.40 million shares of its common stock at a public offering price of $1.50 per share, for gross ...

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

24d ago, source: Morningstar

Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it is preparing to undertake ...

Oragenics, Inc. (OGEN) Interactive Stock Chart - Yahoo Finance

11d ago, source: Yahoo Finance

SARASOTA, Fla., March 18, 2024--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today ...

Oragenics Appoints Kelly As Chief Medical Officer

10d ago, source:

Oragenics, Inc. (OGEN) announced on Monday that James Kelly, a Neurologist, has been appointed as its chief medical officer. Kelly ...

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

11d ago, source: Business Wire

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today ...

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

21d ago, source: ADVFN

Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced that its ...

Oragenics Announces Closing of Public Offering

27d ago, source: Yahoo Finance

SARASOTA, Fla., March 01, 2024--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a company focused on developing unique, intranasal nanoparticle pharmaceuticals ...

Why Beyond Meat Shares Are Trading Higher By Around 56%; Here Are 20 Stocks Moving Premarket

on MSN ago, source:

Prefers This Stock Over Anheuser-Busch Oragenics, Inc. (NYSE: OGEN) shares dipped 43.3% to $1.39 in pre-market trading.

Odyssey Health, Inc. Strengthens Balance Sheet with $8.7 Million in Net Equity

1d ago, source: Finanznachrichten

The increase in net positive equity is due to the sale of its neurological assets to Oragenics, Inc. on December 28, 2023. As part of the consideration for the assets, the Company received eight ...

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

24d ago, source: Yahoo Finance

SARASOTA, Fla., March 05, 2024--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological ...

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

23d ago, source: Stockhouse

Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it is preparing to undertake the ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...